List of Bid Proposal Holders, June 18, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, July 16, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, August 20, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, September 17, 2013

List of Bid Proposal Holders

Iowa DOT staff waterway user charge proposal,1976.

The Iowa DOT reviewed Corps of Engineers accounting records to determine the costs of operating and maintaining a 300 mile section of the Mississippi River. This document reviews the details the study.

List of Bid Proposal Holders, October 4, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, November 19, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, December 17, 2013

List of Bid Proposal Holders

List of Bid Proposal Holders, January 22, 2014

List of Bid Proposal Holders

List of Bid Proposal Holders, March 18, 2014

List of Bid Proposal Holders

List of Bid Proposal Holders, April 15, 2014

List of Bid Proposal Holders

List of Bid Proposal Holders, May 20, 2014

List of Bid Proposal Holders

List of Bid Proposal Holders, June 17, 2014

List of Bid Proposal Holders

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.